Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers

J. R. Conejo, J. Kleeff, A. Koliopanos, K. Matsuda, Z. W. Zhu, H. Goecke, N. Bicheng, A. Zimmermann, Murray Korc, H. Friess, M. W. Büchler

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Syndecan-1 belongs to the syndecan family of cell surface transmembrane heparan-sulfate proteoglycans, which participate in cell proliferation, cell migration and cell-matrix interactions. Decreased expression of syndecan-1 has been observed in some gastrointestinal malignancies, and it is thought that high levels of syndecan-1 correlate with the maintenance of epithelial morphology and inhibition of invasiveness. In our study, we characterized the expression of syndecan-1 in normal, chronic pancreatitis and primary and metastatic human pancreatic cancer tissues, in cultured pancreatic cancer cell lines and in esophageal, gastric, colon, and liver cancers. Pancreatic cancer cell lines expressed syndecan-1 mRNA and protein at variable levels. In addition, these cells also released syndecan-1 into the culture medium. Pancreatic cancer tissues markedly over-expressed syndecan-1 mRNA in comparison with both chronic pancreatitis (2.4-fold increase, p <0.01) and normal pancreatic samples (10.6-fold increase, p <0.01). There was no difference in syndecan-1 mRNA expression between early and advanced tumors. By in situ hybridization and immunohistochemistry, syndecan-1 expression was evident at relatively low levels in the ductal cells and less frequently in acinar cells of the normal pancreas. In chronic pancreatitis, syndecan-1 was present at low to moderate levels in areas with atrophic acinar cells and ductular complexes. In contrast, in pancreatic cancer tissues, syndecan-1 was present at moderate to high levels in the majority of the cancer cells within the tumor mass and also in metastatic lesions of pancreatic tumors. Syndecan-1 mRNA levels in other gastrointestinal malignancies (esophageal, gastric, colon and liver cancers) were not significantly different from the levels observed in the corresponding normal samples. Together, our findings suggest that syndecan-1 expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder and that its role in pancreatic cancer seems to be different from that in other gastro-intestinal malignancies. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)12-20
Number of pages9
JournalInternational Journal of Cancer
Volume88
Issue number1
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Syndecan-1
Gastrointestinal Neoplasms
Pancreatic Neoplasms
Chronic Pancreatitis
Neoplasms
Messenger RNA
Acinar Cells
Liver Neoplasms
Esophageal Neoplasms
Colonic Neoplasms
Stomach Neoplasms
Syndecans
Cell Line
Heparan Sulfate Proteoglycans
Cell Communication

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. / Conejo, J. R.; Kleeff, J.; Koliopanos, A.; Matsuda, K.; Zhu, Z. W.; Goecke, H.; Bicheng, N.; Zimmermann, A.; Korc, Murray; Friess, H.; Büchler, M. W.

In: International Journal of Cancer, Vol. 88, No. 1, 2000, p. 12-20.

Research output: Contribution to journalArticle

Conejo, JR, Kleeff, J, Koliopanos, A, Matsuda, K, Zhu, ZW, Goecke, H, Bicheng, N, Zimmermann, A, Korc, M, Friess, H & Büchler, MW 2000, 'Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers', International Journal of Cancer, vol. 88, no. 1, pp. 12-20. https://doi.org/10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T
Conejo, J. R. ; Kleeff, J. ; Koliopanos, A. ; Matsuda, K. ; Zhu, Z. W. ; Goecke, H. ; Bicheng, N. ; Zimmermann, A. ; Korc, Murray ; Friess, H. ; Büchler, M. W. / Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. In: International Journal of Cancer. 2000 ; Vol. 88, No. 1. pp. 12-20.
@article{d0dd9e498ee7419abc9362dd36306890,
title = "Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers",
abstract = "Syndecan-1 belongs to the syndecan family of cell surface transmembrane heparan-sulfate proteoglycans, which participate in cell proliferation, cell migration and cell-matrix interactions. Decreased expression of syndecan-1 has been observed in some gastrointestinal malignancies, and it is thought that high levels of syndecan-1 correlate with the maintenance of epithelial morphology and inhibition of invasiveness. In our study, we characterized the expression of syndecan-1 in normal, chronic pancreatitis and primary and metastatic human pancreatic cancer tissues, in cultured pancreatic cancer cell lines and in esophageal, gastric, colon, and liver cancers. Pancreatic cancer cell lines expressed syndecan-1 mRNA and protein at variable levels. In addition, these cells also released syndecan-1 into the culture medium. Pancreatic cancer tissues markedly over-expressed syndecan-1 mRNA in comparison with both chronic pancreatitis (2.4-fold increase, p <0.01) and normal pancreatic samples (10.6-fold increase, p <0.01). There was no difference in syndecan-1 mRNA expression between early and advanced tumors. By in situ hybridization and immunohistochemistry, syndecan-1 expression was evident at relatively low levels in the ductal cells and less frequently in acinar cells of the normal pancreas. In chronic pancreatitis, syndecan-1 was present at low to moderate levels in areas with atrophic acinar cells and ductular complexes. In contrast, in pancreatic cancer tissues, syndecan-1 was present at moderate to high levels in the majority of the cancer cells within the tumor mass and also in metastatic lesions of pancreatic tumors. Syndecan-1 mRNA levels in other gastrointestinal malignancies (esophageal, gastric, colon and liver cancers) were not significantly different from the levels observed in the corresponding normal samples. Together, our findings suggest that syndecan-1 expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder and that its role in pancreatic cancer seems to be different from that in other gastro-intestinal malignancies. (C) 2000 Wiley-Liss, Inc.",
author = "Conejo, {J. R.} and J. Kleeff and A. Koliopanos and K. Matsuda and Zhu, {Z. W.} and H. Goecke and N. Bicheng and A. Zimmermann and Murray Korc and H. Friess and B{\"u}chler, {M. W.}",
year = "2000",
doi = "10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T",
language = "English (US)",
volume = "88",
pages = "12--20",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers

AU - Conejo, J. R.

AU - Kleeff, J.

AU - Koliopanos, A.

AU - Matsuda, K.

AU - Zhu, Z. W.

AU - Goecke, H.

AU - Bicheng, N.

AU - Zimmermann, A.

AU - Korc, Murray

AU - Friess, H.

AU - Büchler, M. W.

PY - 2000

Y1 - 2000

N2 - Syndecan-1 belongs to the syndecan family of cell surface transmembrane heparan-sulfate proteoglycans, which participate in cell proliferation, cell migration and cell-matrix interactions. Decreased expression of syndecan-1 has been observed in some gastrointestinal malignancies, and it is thought that high levels of syndecan-1 correlate with the maintenance of epithelial morphology and inhibition of invasiveness. In our study, we characterized the expression of syndecan-1 in normal, chronic pancreatitis and primary and metastatic human pancreatic cancer tissues, in cultured pancreatic cancer cell lines and in esophageal, gastric, colon, and liver cancers. Pancreatic cancer cell lines expressed syndecan-1 mRNA and protein at variable levels. In addition, these cells also released syndecan-1 into the culture medium. Pancreatic cancer tissues markedly over-expressed syndecan-1 mRNA in comparison with both chronic pancreatitis (2.4-fold increase, p <0.01) and normal pancreatic samples (10.6-fold increase, p <0.01). There was no difference in syndecan-1 mRNA expression between early and advanced tumors. By in situ hybridization and immunohistochemistry, syndecan-1 expression was evident at relatively low levels in the ductal cells and less frequently in acinar cells of the normal pancreas. In chronic pancreatitis, syndecan-1 was present at low to moderate levels in areas with atrophic acinar cells and ductular complexes. In contrast, in pancreatic cancer tissues, syndecan-1 was present at moderate to high levels in the majority of the cancer cells within the tumor mass and also in metastatic lesions of pancreatic tumors. Syndecan-1 mRNA levels in other gastrointestinal malignancies (esophageal, gastric, colon and liver cancers) were not significantly different from the levels observed in the corresponding normal samples. Together, our findings suggest that syndecan-1 expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder and that its role in pancreatic cancer seems to be different from that in other gastro-intestinal malignancies. (C) 2000 Wiley-Liss, Inc.

AB - Syndecan-1 belongs to the syndecan family of cell surface transmembrane heparan-sulfate proteoglycans, which participate in cell proliferation, cell migration and cell-matrix interactions. Decreased expression of syndecan-1 has been observed in some gastrointestinal malignancies, and it is thought that high levels of syndecan-1 correlate with the maintenance of epithelial morphology and inhibition of invasiveness. In our study, we characterized the expression of syndecan-1 in normal, chronic pancreatitis and primary and metastatic human pancreatic cancer tissues, in cultured pancreatic cancer cell lines and in esophageal, gastric, colon, and liver cancers. Pancreatic cancer cell lines expressed syndecan-1 mRNA and protein at variable levels. In addition, these cells also released syndecan-1 into the culture medium. Pancreatic cancer tissues markedly over-expressed syndecan-1 mRNA in comparison with both chronic pancreatitis (2.4-fold increase, p <0.01) and normal pancreatic samples (10.6-fold increase, p <0.01). There was no difference in syndecan-1 mRNA expression between early and advanced tumors. By in situ hybridization and immunohistochemistry, syndecan-1 expression was evident at relatively low levels in the ductal cells and less frequently in acinar cells of the normal pancreas. In chronic pancreatitis, syndecan-1 was present at low to moderate levels in areas with atrophic acinar cells and ductular complexes. In contrast, in pancreatic cancer tissues, syndecan-1 was present at moderate to high levels in the majority of the cancer cells within the tumor mass and also in metastatic lesions of pancreatic tumors. Syndecan-1 mRNA levels in other gastrointestinal malignancies (esophageal, gastric, colon and liver cancers) were not significantly different from the levels observed in the corresponding normal samples. Together, our findings suggest that syndecan-1 expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder and that its role in pancreatic cancer seems to be different from that in other gastro-intestinal malignancies. (C) 2000 Wiley-Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033856662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033856662&partnerID=8YFLogxK

U2 - 10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T

DO - 10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T

M3 - Article

C2 - 10962434

AN - SCOPUS:0033856662

VL - 88

SP - 12

EP - 20

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -